Visit the registration desk located in the foyer

This session will review currently available DXA software features that may not be integrated into routine clinical practice along with companion software that expands the utility of DXA imaging.  Finally, discussion of potential opportunities to enhance or extend the technology.

OBJECTIVES

1. Identify currently available software features that have clinical application
2. Review evolving DXA applications that may have future clinical utility
3. Discuss the potential of DXA to expand into new clinical areas

LOCATION

Georgian room

Diane Krueger, BS, CBDT, Researcher

In growing bone, administration of bisphosphonate yields differing effects based on medical condition, age, skeletal site measured, and therapeutic regimen.

OBJECTIVES

1. Describe appearance of bisphosphonate treatment at measured body sites in treated children
2. Examine BP treatment effects over time in children with different conditions
3. Review bisphosphonate treatment approaches used in pediatrics.

LOCATION

Georgian room

Heidi Kecskemethy, MS Ed, RDN, CSP, CBDT, Director of Radiology Research Operations

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment. Coffee and tea will be provided during the breaks.

Meet with our experts in Berkeley:

Hologic Technologist Office Hours with Larry Jankowski

The consideration of how to best report less than 4 vertebrae for spine BMD is frequently discussed. This issue was addressed during the last position development conference. This lecture will review how this should best be evaluated and reported along with taking into account trabecular bone score reporting in this situation as well.

OBJECTIVES

1. Identify the best way to report less than 4 vertebrae on a spine BMD
2. Distinguish between the different methods in which LSC can be reported in this situation
3. Determine how TBS should be evaluated when less than 4 vertebrae are evaluated. Identify currently available software features that have clinical application

LOCATION

Georgian room

Dr. Harold Rosen, MD, CCD, Director of the Osteoporosis Prevention and Treatment Center

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment.

LOCATION: Georgian room

PROGRAM: For over a decade, Trabecular Bone Score (TBS) has been used in clinical setting,  complementing FRAX® and BMD to improve the detection of bone fragilities in patients at risk of fractures. TBS Osteo is the only regulatory software approved worldwide for indirectly evaluating bone microarchitecture status in clinical settings from 2D images, and is supported by four category 1 CPT® codes for reimbursement in the U.S.

Building on 14 years of product evolution to meet clinicians’ needs, the new TBS Osteo v4 software is designed to enhance evaluation capabilities. It represents a significant clinical advancement by offering a broader patient eligibility, and technical interoperability within the radiology practice.

Join Medimaps Group Product Theater to learn more about the new TBS Osteo v4 features and its clinical performance in patients suffering from pathologies impacting bone microarchitecture.

SPEAKERS:

Univ.-Prof. Dr. Didier Hans
Head of Research and Development, Interdisciplinary Center of Bone Diseases at Lausanne University Hospital and CEO & Co-Founder of Medimaps Group

Univ.-Prof. Dr. Karen Hind
Honorary Professor at Lancaster University Medical School, UK and Senior Director of Clinical Affairs, Research and Innovation at Medimaps Group

---

Product Theaters are sponsored presentations and there is no credit available. A boxed lunch will be provided to the first 80 attendees.

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment.

An update on anabolic and antiresorptive therapies and the importance of drug sequence.

OBJECTIVES

1. Understand the benefits and risks of long-term therapy with any single agent
2. Determine the effects of discontinuing the various osteoporosis medications
3. Be familiar with the distinct effects of the various drug sequences in osteoporosis therapy

LOCATION

Georgian room

Benjamin Leder, Professor of Medicine

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment. Coffee and tea will be provided during the breaks.

Meet with our experts in Berkeley:

GE Clinician Office Hours with Dr. Angela Cheung

The importance of optimization of bone health prior to spine surgery is well recognized and being addressed regularly. This lecture will focus on the best ways to assess and enhance bone health prior to spine surgery for improved outcomes.

OBJECTIVES

1. Describe how to best assess bone health prior to spine surgery
2. Determine which treatment option should be considered in different situations along with potential side effects
3. Explain what treatment length should be expected along with potential improvement in outcomes

LOCATION

Georgian room

Paul A. Anderson, MD, MS, Emeritus Professor of Orthopedics

Sarcopenia, the age-related loss of muscle mass and function, is often considered in the context of osteoporosis and fractures.  Despite this, progress in clinical recognition and treatment of sarcopenia has been limited.  Sarcopenia today seems comparable to osteoporosis prior to 1990; a disease without widespread clinical diagnosis for which no pharmacologic therapy exists.  Moreover, the pathogenesis of sarcopenia and osteoporosis are strikingly similar.  Nonetheless, consideration of sarcopenia by osteoporosis clinicians can be done today; reasonable current, and potential future, clinical approaches will be considered.

OBJECTIVES

1. Make use of a syndrome approach to reducing “osteoporosis-related” fractures  
2. Appreciate challenges in operationalizing the diagnosis of sarcopenia  
3. Summarize rational approaches to non-pharmacologic fracture risk reduction therapy including calcium, vitamin D, protein and exercise/falls risk reduction

LOCATION

Georgian room

Neil Binkley, MD, CCD, Professor of Medicine

Difficult bone cases will be reviewed with salient teaching points discussed. A panel of experts will provide opinions as well.

PANELISTS

• Paul Anderson
• Neil Binkley
• Jennifer Kelly
• Rachel Pessah-Pollack

OBJECTIVES

1. Identify how to navigate difficult metabolic bone cases
2. Distinguish between the best tests to order in different clinical scenarios
3. Describe which medications would be best utilized in distinct situations

LOCATION

Georgian room

John J. Carey, MBBChBAO, MS, CCD, FRCPI, Physician in Rheumatology, Osteology, and Medicine / Professor in Medicine

Join us for the Opening Reception in Statler (Exhibit Hall). This networking event is a great opportunity to meet our exhibiting companies, connect with colleagues you haven't seen in a while and meet fellow leaders in skeletal health assessment. Light refreshments will be provided.

Visit the registration desk located in the foyer

Artificial intelligence is well recognized as an emerging and vital part of assessing bone health. This lecture will focus on how we can best utilize and glean important information from radiology films to assess fracture presence and increased future risk.

OBJECTIVES

1. Identify how to best assess the use of AI on the use of radiographs to assess for fractures
2. Determine the limitations of using AI in this setting
3. Distinguish how to best utilize this technology for the future

LOCATION

Georgian room

Ali Guermazi, MD, PhD, MSc, Professor of Radiology & Medicine

Paget's disease is a skeletal growth disorder in which significant abnormalities can occur. This session will help with the identification and treatment of these abnormalities.

OBJECTIVES

1. Understand the pathophysiology of Paget's Disease
2. Become familiar with the radiologic features of Paget's Disease 
3. Understand the management of Paget's DiseaseIdentify currently available software features that have clinical application

LOCATION

Georgian room

Gary Edelson, M.D.,

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment. Coffee and tea will be provided during the breaks.

Meet with our experts in Berkeley:

GE Technologist Office Hours with Diane Krueger

Hypoparathyroidism is a rare but serious disorder with potentially very significant adverse outcomes. This lecture will focus on the importance of its proper identifcation and treatment through the discussion of cases along with a review of the literature. Current and future treatment options will be reviewed.

OBJECTIVES

1. Determine how to best assess and treat patients with hypoparathyroidism
2. Distinguish between the potential risks and benefits of older versus newer treatment options
3. Identify the concerns of preventing potential long term sequelae in patients not treated optimally

LOCATION

Georgian room

Lynn A. Kohlmeier, MD, Director of Endocrinology

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment.

LOCATION: Georgian room

PROGRAM: This program will provide an overview of hypophosphatasia, including:

• Recognition of the biochemical hallmark of HPP
• Identification of common signs and symptoms
• Diagnostic considerations for your practice
• Treatment

SPEAKER: Jacqi Kernaghan, MS, PA-C, DFAAPA

Jacqi Kernaghan, MS, PA-C, DFAAPA, is a certified Physician Assistant and the Associate Director of the Osteoporosis Center of Delaware County with three office locations in southeast Pennsylvania. Jacqi earned her Bachelor of Science in Physician Assistant Studies and her Master of Science in Physician Assistant Studies from Philadelphia University (now Jefferson University).

---

Product Theaters are sponsored presentations and there is no credit available. A boxed lunch will be provided to the first 80 attendees.

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment.

Vitamin D is essential to bone health. Controversies exist in this field regarding optimal replacement. Recent Endocrine Society Guidelines will be reviewed along with how this information should best be taken into context in the treatment of our patients with metabolic bone disorders.

OBJECTIVES

1. Identify how to best screen and treat patients at risk for vitamin D deficiency
2. Describe recent guidelines on this topic
3. Determine how to best utilize this information  in clinical  practice and patient care. Identify currently available software features that have clinical application

LOCATION

Georgian room

Alan Malabanan MD, Clinical Associate Professor, Endocrinology, Diabetes, Nutrition & Weight Management

Visit our Exhibit Hall (Statler Room) to meet with leading companies in Skeletal Health Assessment. Coffee and tea will be provided during the breaks.

Meet with our experts in Berkeley.

GE Clinician Office Hours with Dr. Neil Binkley

Many important diagnostic evaluations by sports medicine specialists are important for the non-orthopedic clinician. Sports medicine is more of a blend of specialities rather than a single specialty, and the care of the athlete requires understanding them.

OBJECTIVES

1. How to approach Relative Energy Deficiency in Sport 
2. How to work around injuries to allow an athlete to safely exercise 
3. How to prevent injury Identify currently available software features that have clinical application

LOCATION

Georgian room

Gillian Wooldridge, DO, CCD,

Fracture Liaison Services are crucial to helping prevent future fractures in very high risk patients. The ideal way in which to implement this service remains debatable. The success and data available on the current FLS program being implemented at MGH to date with the use of Zoledronate early on will be discussed.

OBJECTIVES

1. Recognize FLS as an effective mechanism to narrow osteoporosis treatment gap and fracture secondary prevention as a critical opportunity to identify and treat at-risk patients
2. Evaluate the safety of zoledronic acid administered during initial fracture hospitalization and its effectiveness in improving osteoporosis treatment rate
3. Discuss clinical outcomes of inpatient zoledronic acid for patients admitted for hip fracture

LOCATION

Georgian room

WuQiang Fan, Clinical Director of Fracture Liaison Service

Osteoporosis is a very significant disease with increased fracture risk. This session will explore various ways to approach prevention in patients.

OBJECTIVES

1. Understand the magnitude of changes in bone density and microarchitecture that occur during the menopause transition
2. Know how to identify women at high risk for developing osteoporosis
3. Appreciate a long-term for preventing osteoporosis

LOCATION

Georgian room

Michael R. McClung, MD, FACP, FACE, FASBMR,

LOCATION: Georgian room

The ISCD Annual Business Meeting and Awards Ceremony will feature highlights from the Society and recognize our 2024 and 2025 ISCD Award recipients as well as our Best Case Award recipient. Please join us to hear the officers' report and Dr. Angela Man-Wei Cheung, MD, PhD, FRCPC, CCD give her Presidential Address.

The Annual Business Meeting & Awards Ceremony is open to all voting ISCD members. For those who may wish to watch but are not registered for the conference you may access the meeting using Zoom by registering here.

Visit the registration desk located in the foyer

Osteoporosis and an increase in fracture risk occurs across different GFR levels.  At higher stages of CKD, proper identification of the correct type of metabolic bone disorder being assessed is essential for proper treatment. This lecture will focus on how to best identify and treat patients at risk for future fracture at different stages of CKD.

OBJECTIVES

1. Describe how to best assess bone health and fracture risk across different stages of CKD
2. Distinguish between the different types of metabolic bone disorders that can occur at lower GFR levels
3. Identify which treatments for fracture risk reduction should be considered in different scenarios related to CKD.Identify currently available software features that have clinical application

LOCATION

Georgian room

RECORDING:

We are editing the recording and will make the final version available in the Contents section shortly.

Paul Miller, MD, HDSc (honorary), Medical Director

The concept of treat to target is well recognized across multiple fields of medicine and for some time now has been discussed in the arena of osteoporosis.  This lecture will focus on the concept of treat to target in patients who warrant treatment for being at high risk  for fracture along with which goals should be assessed and discussed with the patients for optimizing treatment.

OBJECTIVES

1. Identify what is considered treat to target in osteoporosis treatment
2. Describe the newer position statement published in this field
3. Determine how to best assess patients on treatment over time along with treatment goals.Identify currently available software features that have clinical application

LOCATION

Georgian room

E. Michael Lewiecki, MD, FACP, FACE, CCD, Director

Join us for coffee in Arlington

Transgender and gender diverse (TGD) people are at increased risk for bone loss due to changes in their hormonal milieu. The ISCD recommends screening for low bone density in TGD people especially in those who are at high risk for bone loss and/or may not reach peak bone mass. This case based session will discuss different clinical situations where bone density screening should be performed and when treatment should be considered.

OBJECTIVES

1. Review ISCD guidelines for screening for low bone density in transgender and gender diverse people  
2. List conditions that might put transgender and gender diverse people at increased risk for bone loss  
3. Discuss potential treatment options for transgender and gender diverse people

LOCATION

Georgian room

Vin Tangpricha, MD, PhD, Professor of Medicine, Eminent Physician